Life Sciences Archive » April, 2020

Life Sciences - April, 2020

448 articles

• DOJ Opioid Indictment Unconstitutional, Drug Distributor Says
• United Cannabis Says It Filed Ch. 11 To Stop Takeover
• Fed. Circ. Tackles Appellate Standing, Boston Scientific IP
• NY AG Slams Sacklers' Tepid Financial Info Disclosures
• Del. Justices Allow Nixing Of Biopharma Officer Salary Suit
• Canadian Pot Co. Unwinds Class Cert. Over Recalled Weed
• 10X Genomics Must Face Bio-Rad, Harvard Patent Suit
• New Pharmacy Bellwether Trial Set For 2021 In Opioid MDL
• DOL Head Says 'Cop Is On The Beat' As Virus Plan Blasted
• Dental Co. Looks To Nix High Court Arbitration Question
• 5 Great-Recession Lessons GCs Must Remember Today
• Fla. Blood Bank Donor Gets Slip-And-Fall Suit Reinstated
• Pandemic May Prompt Legislative Action On Court Deadlines
• Pandemic Creates Extra Cyber Risk For Health Care Providers
• 3D Printing Holds Promise And Risk During Pandemic
• Motions To Compel Video Deposition May Face Barriers In NY
• Del. Justices Uphold Demand For AmerisourceBergen Docs
• Becton Wins 2 Of 3 At PTAB In Medication Dosing IP Row
• Boeing Trust Smacks Teva With Another Suit Over Price Hikes
• County Says Mallinckrodt Shouldn't Get Separate Opioid Trial
• Yale Warns Workers' ADA Suit Would Set Back Wellness Plans
• J&J Beats ERISA Suit Over Asbestos In Baby Powder
• Debevoise, Kirkland Drive $250M PE Infusion For Covetrus
• Dems Say No Reopening Without 'Life-And-Death' Safety Regs
• Virus-Wary Diabetics Urge Bellwether Trials Over Insulin Costs
• CBD Co. Settles FTC Suit Over COVID-19, Cancer Cure Claims
• Coronavirus Q&A: McDermott's Health Chair
• Congress Presses FDA To Curb COVID-19 Testing Fraud
• Lax Regs, COVID-19 Impacts May Mean More Asbestos Suits
• Don't Trust Shkreli To Cure COVID-19, Feds Say
• 6 Antitrust Considerations For Companies During Pandemic
• Judging A Book: Richardson Reviews 'Criminal Dissent'
• J&J Talc Users Get One More Shot At False Ad Class Action
• Merck CEO Among Attys On NJ Virus Panel
• Teva Prevails As Judge Rules Generic Cancer Drugs Infringe
• Feds Bring More Charges In Anti-Price Gouging Campaign
• Ferring, Serenity Trial Delayed After Attys Cite Virus Concerns
• Antares Pharma Beats Suit Over 'Vague' Drug Statements
• Justices Told To Skip Challenge Over Doctrine Of Equivalents
• Enough Already With Opioid Bellwethers, Pharmacies Say
• AFL-CIO Calls DOL's Pandemic Response 'Totally Inadequate'
• Coronavirus Regulations: A State-By-State Week In Review
• NY Judge Dismisses Nabriva Investors' FDA Approval Suit
• Merck Faces Trial Over Immigrant Doctor's Revoked Job
• Accountant Says Pot Co. Fired Her For Catching Tax Scheme
• Perrigo's $163.5M Tax Trial Dates Canceled Amid Virus
• Biotech Exec's Capitalization Quarrel Panned In 2nd Circ.
• Tips For Minimizing Law Firm Liability During COVID-19
• 3 Firms Vie For Lead In Becton Securities Suit
• Cannabis Businesses Should Get Federal COVID-19 Relief
• Mass. Pot Shop's Recreational Licensing Win Tossed
• 3 Recommendations For Cos. Considering Litigation Finance
• Mass. Court Split On Making Scientist Use $10M Award On Lab
• 3 Key Developments As Coronavirus Cases Near 1,000,000
• J&J Can't Boot Experts To Sink Asbestos-In-Talc MDL
• Fed. Circ. Bars Pfizer Appeal Over Roche Antibody Drug IP
• Despite Pandemic, No One Expects OSHA Emergency Regs
• Spinal Surgeon To Pay Gov. $1.75M To Settle Kickback Claims
• Fed. Circ. Won't Revive Boston Scientific IP From Edwards IPR
• McConnell Wants Broad Liability Shield In Next COVID-19 Bill
• Judge Keeps EpiPen Expiration Date Suit Out Of MDL
• Swiss Biotech Firm, Chinese Crypto Miner Boost IPO Pipeline
• WTO Urges Members To Lift Trade Barriers On Virus Supplies
• Gilead Says Feds Used Its Research To Patent HIV Treatment
• Chancery Backs Trustee In Pharma Sale Despite 11th-Hour Bid
• Biotech Firm, Gambling Software Co. Prep IPOs Totaling $83M
• SDNY Chief Judge's May IP Trial Plan Has Lawyers Nervous
• Joint Research Considerations As Biotech Responds To Virus
• Missouri Farm Fights BASF's Bid To Escape $250M Verdict
• A Proposed Technology-Assisted Review Framework
• ERISA Doesn't Trump Drug Benefit Law, Ark. Tells High Court
• Insys Founder's Prison Report Date Pushed Back Amid Virus
• Latham Steers Cancer Therapy Biz's $200M Funding Round
• Best Ways To Use Patent Venue Discovery After TC Heartland
• US Should Decriminalize, Regulate And Tax Marijuana
• MoFo M&A Leader Leaves For Biotech Working On COVID-19
• Alphatec Cites Material Adverse Effects In Ending $122M Deal
• NY Sneaker Salesman Charged With COVID-19 Price Gouging
• Fed. Circ. Affirms Illumina's $27M Patent Win Over Ariosa
• J&J's Efforts To Toss $4.7B Talc Verdict Get Mixed Reception
• Patent Owner's Printed Publication Stance Riles PTAB Judge
• 7th Circ. Rejects Amazon Seller's $500K Trademark Appeal
• Indivior Gets Amicus Cut From 3rd Circ. Suboxone Appeal
• Express Scripts Aims To Toss Suit Over OT For 'Managers'
• Investor Sues CBD Pharma Co. Over Clinical Trial Safety Data
• Trading Firm's Arbitral Award Still Needs Some Clarity
• Fed. Circ. Won't Review Nix Of Merck's $2.5B IP Win
• Harley-Davidson, Others Targeted Over Tech Patent
• WTO Bemoans Lack Of Clarity On COVID-19 Export Curbs
• Revised N. American Trade Deal Will Take Effect July 1
• White & Case Guides Takeda In Asset Sale Worth Up To $670M
• Interlocutory Appeals In MDLs Would Burden Litigants, Courts
• The Pandemic's Impact On Pending M&A
• How Lawyers Can Find Equanimity In Crisis
• FDA Warns Trump-Touted Drugs Have Dangerous Side Effects
• Pot Investor Class Actions Doubled In Past Year
• Bausch Says Insurers Can't Skirt Coverage For Allergan Case
• Small Biz Bankruptcy Rules Come Just In Time For Many
• Ethicon Escapes Covidien Patent Claims In Device Case
• 3M Wins Restraining Order In Price-Gouging Case
• Insys Prosecutors To Appeal Part Of Landmark Guilty Verdict
• 4 Key Developments As Coronavirus Deaths Near 50,000
• Judge Says Drug IP Bench Trial A Go 'Even During Pandemic'
• EPA Pushes Crackdown On Illegal Coronavirus Disinfectants
• 11th Circ. Lets Abortions Continue In Alabama During Virus
• PTAB Won't Review DNA Patent Challenged By Illumina
• Fla. Lab, Ex-CEO Agree To Pay $37M To End SEC Fraud Suit
• SmileDirect's Calif. Dental Board Case Mostly Cut, For Now
• Drugmaker Drops Antitrust Suit Against 'Pharma Bro' Shkreli
• Coronavirus Litigation: The Week In Review
• Georgia Man Claims Zantac Caused His Stage 3 Colon Cancer
• $484B COVID-19 Relief Bill Headed To Trump's Desk
• United Cannabis Must Explain Ch. 11, Given Pot Industry Ties
• Sanofi Takes Flak Over Bid To Escape Suit During Pandemic
• 8th Circ. Clears Arkansas To Block Abortions During COVID-19
• Calif. Landlord Stuck With $6M In Fines For Illegal Pot Shops
• Cos. Making Hand Sanitizer Must Track FDA Guidance
• Calif. COVID-19 Class Actions: Early Trends And Key Defenses
• Fed. Circ. Says Drugmaker Can't Appeal Novartis PTAB Win
• Courts Should Look To 3 Bar Exam Alternatives During Crisis
• FDA Warns CBD Sellers Over Opioid Addiction Relief Claims
• How Life Sciences Cos. Can Adapt To Remote Compliance
• Patenting Personalized Nutrition Is Challenging But Feasible
• Venture-Backed Biotech Firm Raises $120M In Upsized IPO
• Gunderson Dettmer Steers Vaccine Biz's $120M Financing
• Insys Exec Tells 1st Circ. Weil Conflict Should Delay Jail Term
• HHS Vaccine Chief Says Trump Fired Him For Resisting Drug
• Hologic Can't Ban Rival's Surgical Devices After Fed. Circ. Win
• PTAB Weighs Obviousness Standard In Gene Therapy Case
• LA City Atty Says At-Home COVID-19 Test Is False Advertising
• Chancery Rejects $40M Fresenius Fee Shift In Akorn Suit
• 5 Highlights As HHS Earmarks $70B For Coronavirus Relief
• Fired Pot Worker Who Talked To DEA Can't Sue Dispensary
• EU Clears Mylan, Pfizer Unit Deal With Generics Spin Off
• Ill. City Fights Express Scripts' Probe Of Firm In Antitrust Case
• Bausch Execs Try To Nix Derivative Suit Over Fraud Scheme
• NASCAR Driver Hit With Trademark Suit From Pharma Co.
• Colo. Must Give DEA Pharmacy Data With Patient Info
• Shkreli Wants Out Of Prison To Create COVID-19 Treatment
• Liability Insurance Outlook For Opioid Public Nuisance Claims
• How AI-Related Life Sciences Patents Are Examined In Japan
• Justices Urged To End 'Extreme, Excessive' Fed. Circ. 1-Liners
• Nerve Repair Co. Axogen Beats Stock-Drop Suit
• Opioid Funds Should Be Used For Mental Health, Judge Told
• FTC Inks $38M Settlement Over Supplement False Ad Claims
• 3rd Circ. Scraps Lamictal Wholesalers' Antitrust Class Cert.
• Decision To Include Purdue In NY Opioid Trial Not Yet Ripe
• Virtual Mediation A Viable Option For Class Action Litigants
• Are Litigation Funding Documents Protected From Discovery?
• 7th Circ. Ruling Solidifies Circuit Split On Antitrust Standing
• ITC Bans Cholesterol Test Strip Imports From Chinese Co.
• McKesson Settles Derivative Suit Over DOJ Fine For $175M
• What 2 Jurisdiction Rulings Mean For Class Action Defendants
• United Cannabis Corp. Files For Ch. 11 In Colo.
• Fed. Circ. Limits Scope Of Biogen's MS Drug Patent Extension
• New York Accuses Mallinckrodt Of Opioid Insurance Fraud
• Chemours Appeals Arbitration Duty For DuPont Spinoff Bills
• How J&J's $4.7B Appeal Could Shape Missouri's Talc Trials
• Calif. Biz Groups Want Litigation Protection During Pandemic
• Roche Fights Certification Of NJ Water Contamination Class
• SEC Says Fla. Man Bilked Investors $3M In Sham Pot Co. Deal
• BASF Wants Out Of $250M Dicamba Punitive Damages Verdict
• DC Circ. Says EPA's Science Adviser Policy Unlawful
• Senate OKs $480B More Virus Relief For Small Biz, Hospitals
• UK Watchdog Looking Into Stryker's $4B Plan To Pick Up Rival
• Loestrin Buyers' Attys Seek $43M From Antitrust Deal
• More Accused Schemers Deny Horse Doping Charges
• Lawmakers Ask China To Ease Export Curbs In Virus Fight
• Life Sciences Cos. Bring Unique Real Estate Considerations
• As Zantac Litigation Accelerates, MDL Data Collection Is Key
• How COVID-19 Might Uproot Centuries Of Litigation Traditions
• Edwards Lifesciences Can Appeal Heart Device Patent Ruling
• Inovio Execs Hit With Suit On Heels Of COVID-19 Class Action
• Defending Against Nonperformance Of Life Science Contracts
• Anapol Weiss Gets Largest Share Of $3.8M Fee In Sorin MDL
• Chancellor Rips Critics Of Pharma Sale As 'Incredibly Naive'
• Drug Cos. Say Foreign Status Outs Them From Opioid Case
• UK Advances Probe Of Elanco's Sale Of Dog Ear Treatment
• 5th Circ. Bans Medication Abortion In Texas, Citing Pandemic
• Progressives Make Demands For Next Virus Relief Bill
• Insys Founder Says Feds Singling Him Out On Prison Delay
• Wilson Sonsini-Led Oric Pharmaceuticals Launches $75M IPO
• FDA Warns British CBD Seller Over Virus Prevention Claims
• Life Sciences Cos. Should Look Past Litigation During COVID
• Consider Legal Ramifications Before Recording Video Calls
• Coronavirus Q&A: Covington's Life Sciences Chair
• 3rd Circ. Is Raising Standards For Sealing Confidential Docs
• DOJ Won't Challenge Medicine Distributor During Crisis
• Opioid Cos. Hold To Drug Data Pursuit In Chicago Case
• NJ Firm Denied High Court Appeal Over $550M Mesh Award
• Epogen IP Fight Ends With Hospira Paying More Than $70M
• Akebia Gets FibroGen Anemia Drug Patents Invalidated In UK
• 'Excessive' Robins Kaplan Fee Bid Slashed In Covidien Case
• High Court Won't Hear UT's State Immunity IP Argument
• Whistleblower Can Move Gilead FCA Suit To State Court
• Fla. Panel Upholds Denial Of Medical Marijuana Licenses
• Fed. Circ. Revives Heart Monitor Patent Axed Under Alice
• Pa. Judge Rips Aventis' Last-Minute Subpoenas In FCA Fight
• KPMG's Arbitration Bid Nixed In $1.8B Drug Test Co. Fight
• AmerisouceBergen Wants Shared Docs Blocked In Del. Appeal
• Full Fed. Circ. Told Save Of Illumina DNA Patents Flouts Law
• A New Breed Of Antitrust Challenges To FDA's Orange Book
• Opioid MDL Needs New Pharmacy Bellwether, Judge Says
• 3 Tips For Deposing Difficult Witnesses Remotely
• Contract Performance During Pandemic: Lessons From 1918
• WTO Grapples With Telework Amid Coronavirus Pandemic
• Nivea Maker Beats Claims Lotion Was An Unapproved Drug
• J&J Can't Shake Texas Woman's Asbestos Talc Suit In NJ
• COVID-19 IP Catch-Up: 3M, Congress Eye Price Gouging
• UK Litigation Roundup: Here's What You Missed In London
• Treasury Vows To Expedite Iranian COVID-19 Export Requests
• High Court Delays Arguments In Birth Control, PBM Cases
• Cochlear Warns Fed. Circ. OK'd Inflated Damages Road Map
• Purdue Says Ch. 11 Stay Can't Be Lifted For NY Opioid Trial
• AbbVie Execs Want Out Of Humira Kickbacks Suit
• Labaton Sucharow Takes Lead In Cannabis Stock Drop Suit
• Manufacturers Press Mexico To Narrow Shutdown Mandate
• COVID-19 Disclosures Bring Risks For Life Sciences Cos.
• Deals Rumor Mill: General Atlantic, Naspers, Citic Securities
• How Courts Are Shaping Disclosure Of 3rd-Party MDL Funding
• Fed-Up Judge Tells Attys To 'STOP!' With Opioid Filings
• Keryx Proxy Action Ignored 'Tailored Warning,' Judge Says
• COVID-19 Test Providers, Beware Kickback Enforcement Tool
• Novartis Must Face Retaliation Suit Over Kickback Scheme
• MoFo-Led Cancer Treatment Co. Closes On $100M In Funding
• IP Policy Must Focus On COVID-19 Cure, Not Special Interests
• Drug Developer Accused Of Botching 401(k) Plan Management
• PTAB Probes Claim Construction Standard In Dental IP Case
• Fed. Circ. Ruling Lets PTAB Keep Close Eye On Amendments
• J&J Must Face Retrial In Pa. Pelvic Mesh Injury Case
• House Dems Target Exclusivity, Pricing Of COVID-19 Drugs
• Fla. Pain Clinic, Lab To Pay $41M To Settle FCA Claims
• Rice University Pays $3.7M To End Grant Misuse Claims
• Latham Steers Pharma Co. In $100M Follow-On Offering
• Feds Say Medicare Dispute Invalidates True Health Ch. 11 Plan
• Missouri Settles First Complaints About Medical Pot Licensing
• Ex-Theranos CEO's Criminal Trial Delayed Until October
• PTAB Axes University Of Chicago Cancer Treatment Patent
• CARES Act Will Accelerate OTC Drug Development
• Last Doctor Charged In $5M Opioid Ring Will Plead Guilty
• Fed. Circ. Won't Revisit Battle Over Sensipar Generics
• COVID-19 Securities Class Actions May Hinge On Disclosures
• Emerging Trends In COVID-Related Commercial Litigation
• New Jersey's Plan For 2020 Law Grads Is Brilliant
• NY Businessman Settles SEC's Microcap Fraud Suit For $3.5M
• Drug Cos. May Find Real-World Evidence Cuts Both Ways
• Health Hires: Jones Day, Wilson Sonsini, King & Spalding
• 6th Circ. Limits Opioid Claims Against Pharmacies
• Trump Vows Openings By May, Blames WHO For Pandemic
• 5 New COVID-19 Abortion Developments You Should Know
• Ex-Theranos CEO Seeks 2021 Trial After New Charges Emerge
• Coronavirus Regulations: A State-By-State Week In Review
• Calif., 5 Other States Join Antitrust Suit Against Shkreli
• Zimmer Biomet Agrees to $50M Investor Settlement
• Managing E-Discovery Providers In Times Of Crisis
• To Tackle COVID Price Gouging, 3M Turns To Trademark Law
• Brain Disease Research Co. Raises $45M In Funding Round
• COVID-19 Hacks Bring Cyber Hygiene Into Sharp Focus
• Witness Preparation Tips For Your Next Video Deposition
• How 3rd Parties Can Best Limit Fraud Liability Amid COVID-19
• Cooley-Repped Life Sciences Group Prices $121M Offering
• Sanofi, GSK Team Up To Create COVID-19 Vaccine
• 3 Developments As Trump Claims 'Total' Virus-Rebound Power
• BASF Can't Skirt $250M In Dicamba Damages, Monsanto Says
• The Impact Of Distinct Printed Publication Rules In Exams, IPR
• Teva Unit To Pay $540K EPA Fine Over Clean Air, Water Claims
• Mass. Cannabis Regulator Says She's Stepping Down
• Cherokee Tribe Fires Opening Salvo In Opioid Bellwether
• Hemp Co. Says Calif. County Illegally Destroyed $1B Crop
• Takeaways From FDA's Relaxed Rules For Making Face Masks
• Use Of AI To Treat COVID-19 Shows Novel Inventorship Issues
• Coronavirus Q&A: Sidley Austin's Health Practice Chairs
• Upping Hospitals' Liability Defenses For COVID Measures
• Justices Urged To Wade Into Texas' COVID Abortion Ban Fight
• Law360's 2020 Life Sciences Editorial Advisory Board
• Insys Execs Should Stay In Jail During Appeal, Gov't Says
• In Defense Of Virtual Mediation
• 3 Firms Forge Blackstone's $2B Alnylam Pharma Investment
• Fed. Circ. Weighs Undoing $24M Verdict In DNA IP Row
• Fed. Circ. Orders New Trial In Alere Urine-Test Patent Case
• House Dems Seek FTC Answers On Ventilator Maker Merger
• Pharma Cos. Slam Opioid Negotiation Class At 6th Circ.
• Arthrex Asks Justices To Tackle 2 IPR Constitutional Issues
• Telehealth's Not Getting Switched Off After COVID-19 Crisis
• Ballot Backers Ask Calif. Appeals Court To Uphold SF Tax Vote
• 2nd Circ. Won't Rehear Deerfield Insider Trading Appeal
• MDLs Need A New Path To Interlocutory Appeals
• Jailed Pharma Exec Claiming COVID-19 Risk Denied Release
• Pharma Research Co. Accused Of Firing Whistleblowing Exec
• Del. Justices End Suit Over Walgreens' Theranos Deal
• A Call To Action For The Coming Insurance Litigation Siege
• J&J Drops $400M Deal For Takeda's Surgical Patch
• Some Public Nuisance Claims Cut In NY Opioid Suit
• Strategies For Discouraging Nuisance Patent Suits
• 3M Files Trademark Suit Over COVID-19 Mask Price-Gouging
• How A Small Law Firm Adapts To Remote Work
• Don't Just Delay The Bar Exam — Cancel It Forever
• Life Science Cos. Navigate Dicey Path To Public Markets
• Gilead Rips Merck's New Bid To Restore $2.5B Patent Verdict
• Ex-CEO's Threat To Kill Prosecutor Snarls COVID Release Bid
• 4 Key Developments As Coronavirus Nears Possible Peak
• Fla. Health Workers Say China Is Hoarding Protective Supplies
• Daiichi Says Court Should Decide Drug Patent Fight Venue
• Fed. Circ. Revives Nevro Spine Pain IP Axed As Indefinite
• Calif. Small Businesses Sue China For $8T Over COVID-19
• FDA Warns InfoWars Over COVID-19 Claims
• Fed. Circ. Backs EDTX Decision Clearing Needle Co. In IP Suit
• High Court Inaction Paves Way For Increasing FCA Dismissals
• Early Securities Class Actions Highlight COVID Litigation Risk
• Ex-Zimmer Exec's Discharge Claim Cut From Sex Bias Case
• Amazon To Fight Ex-Worker's Medical Pot Suit In State Court
• 1st Circ. Finds No Fraud In Ocular Therapeutix Stock Suit
• Coronavirus Litigation: The Week In Review
• 7th Circ. Is Told National Class Can't Stay In Ill. TCPA Suit
• How Sellers Can Avoid Price-Gouging For 'Essential' Cannabis
• Don't Forget Firm Culture When Adapting To Remote Work
• COVID-19 Test Maker Hits 'Nefarious' Co. With TM Suit
• Juno Awarded Over $1.1B In Final Judgment For IP Case
• Pfizer Beats Viagra MDL After Plaintiffs' Experts Booted
• Intel, Universities Support Freeing Up IP To Fight COVID-19
• Fed Circ. Revives Mylan Bid To Invalidate Relistor Patent
• Fed. Circ. Rules BASF's Polymer Patent Row Wrongly Axed
• GM, Philips Getting $1.1B For Coronavirus Ventilators
• EU Open To 'Comforting' Drugmakers Cooperating Amid Virus
• COVID-19 Countermeasure Protections Are Not Absolute
• 1st Circ. Backs NuVasive's Noncompete With Ex-Sales Rep
• NY AG Seeks Additional Sackler Family Financial Info
• Does COVID-19 Fall Under Insurers' Pollution Exclusions?
• Okla. Wants To Enforce PBM Law Amid COVID-19 Crisis
• FDA Warns More CBD Sellers About Bogus COVID-19 Claims
• SEC Suspends 3 More OTC Stocks Over COVID-19 Concerns
• Cooley-Led BioPharma Raises $96M In IPO At Top Of Range
• J&J Unit Beats Suit Over Defective Breast Implants
• Predicting COVID-19's IP Impact From Past Recessions' Stats
• Antitrust Regulator Suspends Drug Price Probes Amid Virus
• Trump Fleshes Out Export Restrictions On Medical Equipment
• Suit Faults Carnival Unit For 'Ticking Coronavirus Time Bomb'
• Can Cannabis Survive the Virus? Hemp Has A Leg Up
• Calif. Justices Open To Cities Seeking Statewide UCL Relief
• Cahill Gordon Suspends 2020 Summer Associate Program
• Pentax Reaches $43M DOJ Deal Resolving Scopes Charges
• Pfizer Dodges Suit Claiming Lipitor Causes Diabetes
• Sun Pharma Must Face Celgene's Suit Over Generic Revlimid
• Drug Buyers Cut New, Smaller Antitrust Deal With Celgene
• Puerto Rico Board Says COVID-19 Test Kit Orders Broke Law
• Prosthetics Cos. To Divest Business To Allay FTC Concerns
• Mallinckrodt CEO Must Face Deposition In City's Acthar Fight
• 10th Circ. Upholds IRS Summonses For Marijuana Co.'s Info
• Telehealth Startup Involved In Virus Efforts Raises $50M
• Grassley, Neal Seek Tariff Info On Coronavirus Supply Imports
• 5th Circ. Ruling Amplifies Bristol-Myers Class Action Debate
• Greenberg Traurig Fights Conflict Claim In $1B Fraud Suit
• Conducting Court Hearings Remotely: 12 Considerations
• 7 Ways COVID-19 Product Makers Can Mitigate IP Infringement
• Pandemic May Spur Reform Of Lab Test Regulation
• Mylan Investors Get Cert. In EpiPen Securities Fraud Action
• 3 Key Developments As Coronavirus Deaths Top 10,000
• Trump Unveils Deal With 3M To End Mask Production 'Saga'
• Clinic Says ED Treatment Co. Blocking Competition
• Chancery Sets Short Sale Fuse For Troubled Drug Company
• How COVID-19 Could Shake Up Patent Strategies
• Claims Cut From Opioid MDL's Hospital Bellwether
• Aurobindo, Heritage Accused Of Hiding Drug Contamination
• Firm Cost-Cutting Has GCs Watchful But Not Worried — Yet
• SEC Halts Trading For 2 Penny Stocks Over COVID-19 Claims
• 3rd. Circ. Says Press Release Didn't Defame Pharma Co.
• Bayer Looks To Scratch Antitrust Suit Over Flea, Tick Med
• Ex-FTC Atty Leaves Boies Schiller For Davis Wright
• LA City Atty Settles Suit Over Fake At-Home COVID-19 Tests
• Catalent Must Face Fired Worker's Suit Over False Records
• Pa. Panel Says Ballard Spahr Can Arbitrate Malpractice Case
• Arizona Dispensary Warned For Claiming Products Treat Virus
• DOJ OKs Medical Supply Partnership For COVID-19 Response
• 7th Circ. Told New State Law Doesn't Fix Smokable Hemp Ban
• Mylan Gets PTAB To Nix Sanofi's Lantus Patent Claim
• Key CARES Act Implications For Health And Life Sciences
• Schumer Calls For Military 'Czar' To Oversee Medical Supplies
• Baxter, Hospira Beat Saline Price-Fixing Class Action Again
• E-Cigarette Deadline Extended Amid COVID-19 Pandemic
• International Orgs Rally To Preserve COVID-19 Supply Chain
• The Era Of Video Mediation Is Here — Or Is It?
• High Court Won't Hear Respiratory Treatment Patent Suit
• COVID-19 Highlights BigLaw Need For Emotional Intelligence
• D&O Insurance Tips For Coronavirus-Related Claims
• High Court Won't Weigh DOJ Dismissal Power In FCA Cases
• Ex-Hospital Owner Sanctioned For Holding Info In Clinic Fight
• States' Suit Touted For Bellwether In Generics Price-Fix Case
• Chancery Finds Fraud In Cancer Drug Firm's Spinoff Deal
• Fed. Circ. Lifts Bar On Eye Device Maker's Speech In IP Fight
• Justices Asked To Clarify Gateway Arbitration Question
• Pot Co. Acreage Scraps $120M Deal Amid Virus Cutbacks
• Venture-Backed Firms Could Miss Out On Virus Relief Loans
• Ex-Employees Say $5.5M Deal Can't Stop Retaliation Suit
• Key Issues As Automakers Shift To Medical Device Production
• Will COVID-19 Transform The Cannabis Industry?
• WTO Charts Lofty Tariffs On Essential COVID-19 Supplies
• Melinta's Ch. 11 Exculpation Runs To Plan Date, Court Rules
• The Pandemic's Early Effects On Foreign Trade, Investment
• Judicial Shaming Of Attys Is Troubling Even During Pandemic
• McKesson Again Wants Out Of Antitrust-Linked Derivative Suit
• 3M Hits Back After Trump's Call To Stop Exporting N95 Masks
• What It's Like To Join A Law Firm In The COVID-19 Era
• Don't Be Social Media Distancing: LinkedIn Tips For Lawyers
• Health Hires: Akin Gump, K&L Gates, EIP, Oric Pharma
• Supreme Court Postpones April Argument Session
• Novartis And Aurobindo Scrap $900M Deal Amid FTC Probe
• 19 Deny Charges In Alleged Horse Doping Scheme
• Federal Law Stops Pot Investor From Recovering $4.7M Loans
• IRS Wrongly Kept $400K From Electronic Parts Co., Suit Says
• Minn. AG's Insulin Pricing Suit Survives, Minus RICO Claims
• CBD Co. Latest Target In COVID-19 Scam Enforcement
• Eli Lilly Says Genentech Owes $10M In 'Unwinnable' Suit Fees
• Melinta Gets OK For Ch. 11 Equity Swap Plan With Creditor
• Defending Against A Wave Of Hand Sanitizer Class Actions
• Animal CBD Dealer Sued For Shorting Supplier On $6M Deal
• Emergency Laws Protect Cos. Enlisted In COVID-19 Fight
• 'Pharma Bro' Shkreli Aims Another Blow At Kidney Drug Suit
• Remote Depositions: Coming To A Home Office Near You
• Ways Lawyers Can Support The Most Vulnerable Right Now
• Virus Heightens Importance Of Drug Shortage Reports To FDA
• COVID-19 Shows Need For Stronger Diagnostic IP Protection
• Merck, Takeda Unit Beat Off-Label FCA Kickbacks Suit
• VC Firm Closes On $1.1B Fund For New Biotech Cos.
• Arch Snags $1.46B For Pair Of Biotech-Focused Funds
• IRS May Have Missed $243M In Pot Biz Taxes, TIGTA Says
• Insurance Groups Tell Justices PBM Law Would Upend ERISA
• 10x Genomics Reveals Ransomware Attack Amid Pandemic
• Justice Delayed: Coronavirus Halts Opioid, Cancer Trials
• UK Man Snuck Fake Coronavirus Meds Into Calif., Feds Say
• Hemp Co. Says Seed Producer Cutting It Out of US Sales
• Promoter Disclosed 'Cobra Venom' Co. Payment, Judge Says
• Fed Agencies Flag Ex-NFLer For Claiming CBD Cures Virus
• Pfizer Gets Rival's Epinephrine Injection Patent Killed
• Fed. Circ. To Air Live Audio Of Oral Arguments Amid COVID-19
• Canadian Cannabis Grower To Restructure With $2.8M Loan
• Senate Bill Would Expand Term For COVID-19 Treatment IP
• Theranos Judge Rips 'Tone' Of Attys' Pandemic-Related Filing
• Pharmacies' Doctor Claims Dropped From Ohio Opioid MDL
• Ex-Rep. Collins Asks To Delay Sentence Over COVID-19
• Autoimmune Therapy Biz Raises $80M In Series B Round
• PTAB Upholds 3 Teva Migraine Patents Challenged By Eli Lilly
• What If Gov't Allows Patent Infringement For COVID-19 Drugs?
• Telehealth During COVID-19: New Rules And Considerations
• FDA Orders Heartburn Meds Off Shelves Over Cancer Risk
• Cooley-Led Life Sciences Firm Seeks To Raise $75M In IPO
• EU To Suspend VAT On Medical Supplies Amid Pandemic
• Confronting The Challenges Of Virtual Mediation
• Akorn Says Credit Default Brings It To Brink Of Bankruptcy